Top news of the week: 14.03.2023.
QurAlis Closes $88 Million Series B Financing to Advance Precision Medicines for Neurodegenerative Diseases
/PRNewswire/ -- QurAlis Corporation, a clinical-stage biotechnology company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS)...
FTSE Women Leaders
Trust Plc Alliance Trust Plc Allianz Technology Trust Plc Apax Global Alpha Ltd Ascential Plc Ashmore Group Plc ASOS Plc Assura Plc AVI Global Trust Plc Baillie Gifford Japan …
J&J-backed startup launches with $100M to build better brain drugs
Rapport Therapeutics aims to find new so-called receptor-associated proteins that could serve as targets for neurological disease medicines. Its most advanced drug is already in early-stage ...
Neurological Precision Therapy Company Rapport Therapeutics Launches with $100 Million Series A
Rapport Therapeutics which develops targeted small molecule drugs for neurological disorders launched with a $100 million Series A financing.
Sam Altman invested $180 million into a company trying to delay death
Can anti-aging breakthroughs add 10 healthy years to the human lifespan? The CEO of OpenAI is paying to find out.
Can Silicon Valley stop the next COVID?
The booming pandemic-tech industry is attracting billions from VCs. Can a Silicon Valley-style disruption actually prevent the next deadly outbreak?
How generative AI could transform the $30 billion biotech industry, speeding up everything from drug discovery to DNA sequencing
Generative AI is supercharging the way biotech startups operate. Here's how the technology is being used by the next generation of biotech startups.
GPCR-targeting drugs: A renewed focus on a ubiquitous group of proteins
As many as a third of FDA-approved drugs target GPCRs in some fashion, with uses ranging from treating diabetes to pain. But biotech startups say there’s still room to develop more.